arrow
A

Adriano Pellicelli

san camillo forlanini hospital
H指数:27
被引数:2,572

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database

2024年意大利慢性乙型肝炎和德尔塔病毒诊断患者的估计:基于国家真实世界数据库的研究

2025-09-040
OAAI
Transarterial Radioembolization Can Downstage Intermediate and Advanced Hepatocellular Carcinoma to Liver Transplantation
2024-09-170
PRE
YBulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
2024-02-011
PRE
Prevalence and Characterization of Resistance Profiles of Unusual HCV Subtypes in Italy within the Italian Resistance Network Vironet C
2024-02-010
PRE
Association between gut-derived endotoxins and porto-sinusoidal vascular disorder with portal hypertension

肠源性内毒素与门窦血管疾病与门脉高压的关系

2023-09-204
PRE
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

奥贝胆酸治疗肝硬化原发性胆汁性胆管炎患者严重不良事件和无反应的预测因素

2022-08-2314
OAAI
Real-world experience with obeticholic acid in patients with primary biliary cholangitis

原发性胆汁性胆管炎患者使用奥贝胆酸的真实世界经验

2021-04-0156
OAAI
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
2020-05-157
OAAI
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort
2020-02-011
PREAI
VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
2020-02-010
PREAI
Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
2020-02-010
PREAI
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database
2019-04-010
PREAI
Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance
2019-04-010
PREAI
Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
2019-02-010
PREAI
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
2019-02-010
PREAI
Real life experiences in HCV management in 2018
2019-01-157
OAAI